Clinical trialNCT02873338CompletedPhase 2Interventional

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

SponsorJazz PharmaceuticalsEnrollment75Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This was an exploratory Phase 2, open label, randomized, multicenter, parallel group study to determine whether there was evidence that the addition of dociparstat (CX-01) at 2 different does levels to standard induction therapy (cytarabine+idarubicin, "7+3") and consolidation therapy had an additive therapeutic effect for subjects newly diagnosed with acute myeloid leukemia (AML) when compared with subjects receiving standard induction chemotherapy alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Stephen Marcus, MD
Cantex Pharmaceuticals Inc.
Study DirectorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, San Diego, Moores Cancer Center
La Jolla, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
George Washington University
Washington D.C., District of Columbia, United States
Franciscan St. Francis Health
Indianapolis, Indiana, United States
June E. Nylen Cancer Center
Sioux City, Iowa, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Tulane University/tulane Cancer Center
New Orleans, Louisiana, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Allina Health - Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States
Northwell Health, Monter Cancer Center
Lake Success, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of Cincinnati
Cincinnati, Ohio, United States
Oregon Health & Science University Knight Cancer Institute
Portland, Oregon, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Tennessee Oncology/sarah Cannon Research Institute
Nashville, Tennessee, United States
Baylor Research Institute/baylor Sammons Cancer Center/baylor University Medical Center
Dallas, Texas, United States
Methodist Healthcare System of San Antonio
San Antonio, Texas, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Lds Hospital
Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cytarabine →Dociparstat sodiumIdarubicin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2016
Primary completion: 30 Jun 2019
Completion: 30 Jun 2019
Last update posted: 7 Sept 2023
Registered enrollment: 75
Registry id: NCT02873338

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.